Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) von Savona, M.R, Garcia-Manero, G, Roboz, G.J, Walsh, K.J, Kropf, P.L, Issa, J.P, O’Connell, C.L, Tibes, R, Yee, K.W.L, Stock, W, Lunin, S, Berdeja, J.G, Naim, S, Hao, Y, Azab, M, Kantarjian, H

Volltext

Dasatinib promotes ATRA-induced differentiation of AML cells von Kropf, P L, Wang, L, Zang, Y, Redner, R L, Johnson, D E

Volltext

60 - Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) von Savona, M.R., Garcia-Manero, G., Roboz, G.J., Walsh, K.J., Kropf, P.L., Issa, J.P., O’Connell, C.L., Tibes, R., Yee, K.W.L., Stock, W., Lunin, S., Berdeja, J.G., Naim, S., Hao, Y., Azab, M., Kantarjian, H.

Volltext

Src family kinase gene targets during myeloid differentiation: identification of the EGR-1 gene as a direct target von Jones, J E, Wang, L, Kropf, P L, Duan, R, Johnson, D E

Volltext

S879 RESULTS OF ASTRAL‐1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN‐AML) NOT ELIGIBLE FOR INTENSI... von Fenaux, P., Gobbi, M., Kropf, P.L., Mayer, J., Roboz, G.J., Döhner, H., Krauter, J., Döhner, K., Robak, T., Kantarjian, H., Novak, J., Jedrzejczak, W., Thomas, X., Ojeda‐Uribe, M., Miyazaki, Y., Min, Y. H., Yeh, S.‐P., Brandwein, J., Gercheva‐Kyuchukova, L., Demeter, J., Griffiths, E., Yee, K., Azab, M., Issa, J.‐P.

Volltext